In the US, Abciximab (abciximab systemic) is a member of the drug class glycoprotein platelet inhibitors and is used to treat High Risk Percutaneous Transluminal Angioplasty.
US matches:
- Abciximab
- Abciximab Intravenous
Scheme
Rec.INN
ATC (Anatomical Therapeutic Chemical Classification)
B01AC13
CAS registry number (Chemical Abstracts Service)
0143653-53-6
Chemical Formula
C2101-H3229-N55-O673-S15
Molecular Weight
47462
Therapeutic Categories
Biological response modifier, BRM
Antiplatelet agent, glycoprotein IIb/IIIa-receptor antagonist
Chemical Name
Immunoglobulin G (human-mouse monoclonal c7E3 clone p7E3VHhCy4 Fab fragment anti-human glyocoprotein IIb/IIIa receptor), disulfide with human-mouse monoclonal c7E3 clone p7E3VKhCK light chain
Foreign Names
- Abciximabum (Latin)
- Abciximab (German)
- Abciximab (French)
- Abciximab (Spanish)
Generic Names
- Abciximab (OS: USAN, BAN)
- c7E3 (IS)
Brand Names
- ReoPro
Centocor, Austria; Centocor, Bulgaria; Centocor, Czech Republic; Centocor, Denmark; Centocor, Luxembourg; Centocor, Netherlands; Centocor, Norway; Centocor, Poland; Eli Lilly, Canada; Eli Lilly, United Kingdom; Eli Lilly, Netherlands; Eli Lilly, South Africa; Lilly, Australia; Lilly, Belgium; Lilly, Brazil; Lilly, Switzerland; Lilly, Chile; Lilly, Germany; Lilly, Spain; Lilly, Finland; Lilly, Greece; Lilly, Hong Kong; Lilly, Ireland; Lilly, Israel; Lilly, India; Lilly, Iceland; Lilly, Italy; Lilly, Sri Lanka; Lilly, Mexico; Lilly, Malaysia; Lilly, New Zealand; Lilly, Peru; Lilly, Romania; Lilly, Serbia; Lilly, Russian Federation; Lilly, Sweden; Lilly, Singapore; Lilly, Thailand; Lilly, Taiwan; Lilly, United States
- Réopro
Lilly, France
International Drug Name Search
Glossary
BAN | British Approved Name |
IS | Inofficial Synonym |
OS | Official Synonym |
Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
USAN | United States Adopted Name |
Click for further information on drug naming conventions and
International Nonproprietary Names.